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One of the main challenges of implementing digital breast
tomosynthesis (DBT) into the UK screening programme is the known
increased time to read DBT than digital mammography (2D) cases.
We investigated in detail the nature of reading normal and abnormal
DBT images by a group of experienced DBT radiologists to
determine if there were image inspection time differences. Seven
Italian radiologists, with 2-7 years of DBT screening experience, read
two sets of 20 DBT test cases comprising normal, benign and malig-
nant appearances. As well as their reporting decisions about each
case, their visual search behaviour and pad control were recorded.
All participants read the cases as an initial 2D overview followed by
DBT views. Excluding any reporting time, they spent an average of
1:05s on each case, comprising 14s reading the initial 2D overview
and then 51s examining the DBT view, (p=0.001). There was no sig-
nificant difference in overall reading time between normal (1:03s)
and abnormal cases (1:07s, p=0.53) and little difference in reading
time for the 2D overview for either normal (15s) or abnormal cases
(13s, p=0.1335). Additionally there was no significant difference in
time for normal (48s) and abnormal cases (54s, p=0.3411) when
these were examined as DBT images. It is concluded that a similar
image inspection time is found, irrespective of whether a case is nor-
mal or abnormal. The image inspection times here are faster than
previously have been reported by very experienced DBT readers.
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Purpose
To assess concordance of mammographic changes post neoadjuvant
chemotherapy (NAC) with pathological Miller Payne Score.
Background
Performing mammographic tumour evaluation before and after NAC
allows radiological assessment of tumour response to treatment prior
to surgical excision. The Miller Payne (MP) Score is a histopathological
five-point grading system which assesses tumour response to NAC. This
is an independent predictor of overall patient survival.
Materials and methods
Retrospective data were collected on all patients who completed
NAC in our centre in 2016 (N=41) for breast carcinoma. Patients
underwent mammography before and after NAC, prior to surgical
tumour excision. Mammographic response was measured by
calculating the difference between maximum tumour diameter pre
and post NAC.
Results
100% of patients (N=11) who had pathologic complete response, or
MP grade 5 response (no malignant cells identifiable), had
mammographic complete response. Mean mammographic tumour
reduction in patients (N=7) with MP grade 4 response (greater than
90% loss of tumour cells) was 83%, in patients (N=9) with MP score
of 3 (30-90% loss of tumour cells) was 75%, in patients (N=12) with
MP score of 2 (0-30% tumour loss) was 25% and in patients (N=2)
with MP score of 1 (no loss of tumour cells) was 33.5%.Conclusion
Mammographic response correlates with pathological response in
patients with MP score of 5, however similar correlation does not
exist in other MP scores. Larger studies incorporating other imaging
modalities would be useful.
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Introduction
Study to evaluate the imaging appearance/histology of all biopsied
breast lesions in patients 25 to 30 presenting over six years. As per
national guidelines, typical appearing R3 lesions <3 cm in patients
<25 years are not routinely biopsied. We hoped to increase that age
limit to 30.
Methods
Retrospective study of patients aged 25-30 presenting for TAC over 6
years, allocated a score of R3, R4 or R5. 534 patients reached criteria.
Study points included radiology score; imaging features (fibroaden-
oma-like/non fibroadenoma-like; size; atypical features); histology.
Results
25/534 (4.6%) allocated R4, R5 or R3/R4. 14 (2.6%) of these
diagnosed with invasive malignancy.
509/534 (95.3%) allocated a score of R3.
502 of these proceeded to biopsy.1 with score R3 demonstrated
invasive malignancy on biopsy histology, however the lesion
demonstrated atypical appearances on review of imaging.
50/534 (9.3%) allocated a score B3 and proceeded to excisional
biopsy. None of these lesions demonstrated invasive malignancy. 5
(0.8%) Phyllodes in total diagnosed, 4 < 3cm.
If this was our routine practise, we would NOT have missed an
invasive cancer. We would not have initially diagnosed 4 phyllodes
tumours < 3cm, however their natural history suggests these
patients would have re-presented with an enlarging mass.
Conclusion
We suggest that in patients aged 30 or less where a “fibroadenoma-
like” R3 lesion demonstrates a typical benign appearance, initial
biopsy could be avoided and clinical follow-up following appropriate
counselling could be employed.
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Introduction
At present many breast units, including ours, undertake annual
mammography for 5 years in patients with B3 lesions associated
with a longer term risk of developing cancer (risk lesions), but the
optimal frequency and length of surveillance is unclear. We have
reviewed the development of cancer in a group of our patients with
risk lesions undergoing surveillance.
Materials and Methods
Retrospectively from the hospital appointments database we identified
all patients with risk lesions undergoing surveillance mammograms
from April 2010 to the end of March 2015 and reviewed their records
until the end of March 2017. At this time diagnosis was made by 14G
core biopsies combined with 10G vacuum-assisted biopsy or diagnostic
excision to exclude adjacent co-existing malignancy.
